TABLE 2

Overall mean levels of CAT, CuZnSOD, GPX, and MnSOD mRNA expression in normal and hyperglycemic conditions in the study groups

Diabetic patients with nephropathy (n = 26)
Diabetic patients without complications (n = 15)
Normal control subjects (n = 10)
Glucose
Glucose
Glucose
11 mmol/l31 mmol/l11 mmol/l31 mmol/l11 mmol/l31 mmol/l
CAT3.1 ± 0.241.9 ± 0.25*1.0 ± 0.322.6 ± 0.352.9 ± 0.324.5 ± 0.27
CuZnSOD1.6 ± 0.170.9 ± 0.070.8 ± 0.153.0 ± 0.351.4 ± 0.262.9 ± 0.48
GPX3.2 ± 0.27#1.7 ± 0.191.2 ± 0.072.7 ± 0.262.6 ± 0.444.5 ± 0.37
MnSOD4.5 ± 0.484.1 ± 0.5§3.7 ± 0.44.1 ± 0.445.9 ± 0.276.2 ± 0.17
  • Data are means ± SE. P values are all vs. PBMCs from diabetic nephropathy cultured under hyperglycemic conditions.

  • *

    * versus uncomplicated, P = 0.09, and vs. control, P < 0.001.

  • versus uncomplicated, P < 0.001, and vs. control, P < 0.001.

  • versus uncomplicated, P = 0.002, and vs. control, P < 0.001.

  • §

    § versus control, P = 0.01.

  • versus uncomplicated 11 mmol/l d-glucose, P = 0.00001.

  • #

    # versus uncomplicated 11 mmol/l d-glucose, P = 0.00001. Diabetic patients with nephropathy: 11 mmol/l d-glucose vs. 31 mmol/l d-glucose: CAT mRNA, P = 0.002; CuZnSOD mRNA, P = 0.0002; GPX mRNA, P = 0.0001.